PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

After demonstrating significant improvement in progression-free survival, and now overall survival as well, the combination ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...

Jan 16 (Reuters) - Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood ...

The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Genmab plans to present full results at an upcoming medical meeting.

year survival rates averaged across all cancers have never been higher, with 7-in-10 cancer patients living past 5 years post-diagnosis.

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

North Chicago, Illinois Monday, January 19, 2026, 15:00 Hrs [IST] ...